BOSTON & SAN DIEGO–(BUSINESS WIRE)–Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Terry-Ann Burrell to its Board of Directors. Ms. Burrell currently serves as Chief Financial Officer of Beam Therapeutics.
“We are very pleased to welcome Ms. Burrell to our board. With an exceptional track record of executive financial leadership and multi-billion-dollar financings in the biotech and pharma sectors, Ms. Burrell is an ideal addition,” said Abraham Ceesay, Chief Executive Officer of Rapport. “As we continue our journey to establish the leading precision neuroscience company, expanding our board with Ms. Burrell will undoubtedly propel our efforts to achieve our mission.”
Prior to Beam Therapeutics, Ms. Burrell was with J.P. Morgan for over a decade, most recently serving as Managing Director in the healthcare investment banking group. There, covering the biotechnology and pharmaceutical sectors, Ms. Burrell helped to execute over $10 billion in equity and equity linked financings and more than $50 billion in M&A transactions. Prior to J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics. Ms. Burrell holds an MBA from New York University Leonard N. Stern School of Business and a B.A. from Harvard University.
“This is an important moment for Rapport as the company prepares for both important clinical milestones and the complexities of the biotech financial landscape,” said Ms. Burrell. “Rapport is poised for success and I look forward to leveraging my considerable experience working with early stage biotech companies to support this team as it charts new territory in neuromedicine.”
About Rapport (www.rapportrx.com)
Rapport is developing a new class of precision neuromedicines that could give patients better alternatives to current treatments for neurological and psychiatric diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance and discontinuation. By more precisely targeting the neural circuits and cell types where diseases originate, Rapport’s approach has the potential to reduce the unwanted drug-target interactions that lead to these issues. The company’s platform, built and refined over the past decade by its founding scientific team, achieves precision through the discovery and targeting of receptor-associated proteins, or RAPs, which display regional or neural circuit-specific expression. Rapport has ongoing clinical trials and discovery-stage programs in epilepsy, hearing, pain, and psychiatric disorders.
